Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Replagal in Canadian Fabry Disease Patients
NCT01298141Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2011
- Primary completion
- Sep 2017
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Started Aug 2011; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT01298141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298141.